Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PCVXNASDAQ:PTCTNASDAQ:RYTMNASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePCVXVaxcyte$36.99+6.3%$32.26$27.66▼$121.06$4.77B1.21.43 million shs1.58 million shsPTCTPTC Therapeutics$52.13+0.8%$46.33$28.72▼$58.38$4.10B0.51869,689 shs936,061 shsRYTMRhythm Pharmaceuticals$68.11+2.9%$60.80$38.90▼$68.58$4.33B2.3557,016 shs707,935 shsSNDXSyndax Pharmaceuticals$11.45+2.6%$11.32$8.58▼$25.07$960.28M0.741.80 million shs1.34 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePCVXVaxcyte0.00%+13.47%+17.62%-48.03%-49.63%PTCTPTC Therapeutics0.00%+6.78%+22.53%-0.87%+37.18%RYTMRhythm Pharmaceuticals0.00%+11.00%+12.17%+34.10%+70.62%SNDXSyndax Pharmaceuticals0.00%+8.33%+4.00%-14.68%-40.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPCVXVaxcyte2.6193 of 5 stars4.61.00.00.02.61.70.0PTCTPTC Therapeutics3.1902 of 5 stars3.31.00.04.41.90.80.0RYTMRhythm Pharmaceuticals3.7086 of 5 stars3.51.00.04.32.70.80.6SNDXSyndax Pharmaceuticals3.2052 of 5 stars3.51.00.04.42.50.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePCVXVaxcyte 3.10Buy$136.50269.02% UpsidePTCTPTC Therapeutics 2.64Moderate Buy$63.7522.29% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$76.6212.49% UpsideSNDXSyndax Pharmaceuticals 2.91Moderate Buy$35.91213.62% UpsideCurrent Analyst Ratings BreakdownLatest SNDX, PCVX, RYTM, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $94.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/7/2025PTCTPTC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.005/7/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.005/7/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.005/7/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $67.005/7/2025PTCTPTC TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$50.00 ➝ $40.005/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.005/6/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.00(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/APTCTPTC Therapeutics$1.77B2.33$2.51 per share20.80($10.85) per share-4.80RYTMRhythm Pharmaceuticals$136.86M31.66N/AN/A$2.87 per share23.73SNDXSyndax Pharmaceuticals$43.72M22.53N/AN/A$6.53 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePCVXVaxcyte-$402.27M-$3.99N/AN/AN/AN/A-23.53%-22.20%8/5/2025 (Estimated)PTCTPTC Therapeutics-$626.60M$6.51N/AN/AN/A-50.32%N/A-16.44%8/14/2025 (Estimated)RYTMRhythm Pharmaceuticals-$184.68M-$2.81N/AN/AN/A-230.07%-367.36%-77.47%8/5/2025 (Estimated)SNDXSyndax Pharmaceuticals-$209.36M-$3.86N/AN/AN/AN/A-64.34%-57.72%8/7/2025 (Estimated)Latest SNDX, PCVX, RYTM, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/A5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPCVXVaxcyteN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPCVXVaxcyteN/A17.8817.88PTCTPTC TherapeuticsN/A2.102.04RYTMRhythm PharmaceuticalsN/A3.493.34SNDXSyndax PharmaceuticalsN/A6.996.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPCVXVaxcyte96.78%PTCTPTC TherapeuticsN/ARYTMRhythm PharmaceuticalsN/ASNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipPCVXVaxcyte3.10%PTCTPTC Therapeutics5.50%RYTMRhythm Pharmaceuticals6.10%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePCVXVaxcyte160129.00 million120.77 millionOptionablePTCTPTC Therapeutics1,41079.26 million72.88 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million58.02 millionOptionableSNDXSyndax Pharmaceuticals11086.05 million81.86 millionOptionableSNDX, PCVX, RYTM, and PTCT HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 7 at 3:32 AM | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 5 at 4:01 PM | globenewswire.comAmeriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)June 5 at 3:14 AM | marketbeat.comKura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With SyndaxJune 3, 2025 | biospace.comNuveen Asset Management LLC Trims Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)June 1, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DEJune 1, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLPMay 31, 2025 | marketbeat.comVoloridge Investment Management LLC Takes $1.05 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 31, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 4.9% - Still a Buy?May 30, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $35.91 Average Target Price from BrokeragesMay 30, 2025 | americanbankingnews.comSyndax Announces Participation in June Investor ConferencesMay 29, 2025 | globenewswire.comPolar Asset Management Partners Inc. Invests $1.12 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 29, 2025 | marketbeat.comMillennium Management LLC Has $7.76 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 28, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 28, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LPMay 27, 2025 | marketbeat.comTwo Sigma Advisers LP Has $7.09 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 26, 2025 | marketbeat.com121,539 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Acquired by Man Group plcMay 26, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 5.7% - Here's WhyMay 25, 2025 | marketbeat.comTwinbeech Capital LP Boosts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 23, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 23, 2025 | marketbeat.comSoleus Capital Management L.P. Boosts Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDX, PCVX, RYTM, and PTCT Company DescriptionsVaxcyte NASDAQ:PCVX$36.99 +2.19 (+6.29%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$36.98 -0.01 (-0.03%) As of 06/6/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.PTC Therapeutics NASDAQ:PTCT$52.13 +0.40 (+0.77%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$51.00 -1.13 (-2.17%) As of 06/6/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$68.11 +1.93 (+2.92%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$72.67 +4.56 (+6.70%) As of 06/6/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Syndax Pharmaceuticals NASDAQ:SNDX$11.45 +0.29 (+2.60%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$11.44 0.00 (-0.04%) As of 06/6/2025 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
